Dra. María Sitges Berrondo
INVESTIGADOR TITULAR "C" T.C.
Instituto de Investigaciones Biomédicas
Sede del Tercer Circuito Exterior
Edificio "B", 2° Piso, Lab.B-249 Ofic.B-248
Ofic. 5622-8960 Lab. 5624-8973
ÁREAS DE TRABAJO
María Sitges (MS) obtained the “Diplome Universitaire d'Etudes Scientifiques (section Chimie-Biologie) at the “Université Claude Bernard” in Lyon, France in 1974. In 1980 MS obtained a degree in Biology at the Faculty of Sciences, Universidad Nacional Autónoma de México (UNAM), that is the largest and more prestigious University in México. In 1984 MS obtained a Master degree in Neurochemistry and in 1987 a Doctorate degree in Molecular Biology at the UNAM. In 1990 MS worked as a visiting professor in the "Neuroscience Programm" at Tufts University, in Boston, Massachusetts, USA. At present MS is a senior scientists and professors at the Instituto de Investigaciones Biomédicas, one of the largest Institutes in the campus of the UNAM. For almost 30 years, MS research has been focused on understanding the Neurochemical mechanisms underlying cerebral presynaptic physiology. In MS laboratory a variety of in vitro and in vivo model systems are utilized to identify and characterize the anticonvulsant profile and potential mechanism of action of established and new antiepileptic drugs. Using these models in the last decade MS has unmask the great potential of vinpocetine in the control of seizures. A phase III study now is being run on refractory epileptic patients. MS has published more than 50 original research papers as corresponding author, obtained several patents, several research projects and sponsor of several PhD students. MS has been recognized with several awards including the Dr. Eduardo Liceaga award from the National Academy of Medicine 1992 and the National Chamber of the Pharmaceutical Industry clinical investigation award 2012. MS has been member of several academic committees, chief of several Departments, including the Celular Biology and Physiology Department at the UNAM, and member of various international scientific societies including the International Society for Neurochemistry.
INTEGRANTES DE GRUPO
Herrera-Mundo N and Sitges M . Vinpocetine and α-tocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings. J. Neurochem. 124 (2):233-240. 2013
Sitges M , Aldana BI , Gómez CD and Nekrassov V. The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizure. Epilepsy & Behavior 25: 511-516. 2012
Aldana BI and Sitges M . Sertraline inhibits presynaptic Na+ channel mediated responses in hippocampus isolated nerve endings. J. Neurochem. 121: 197-205. 2012.
Sitges M , Sanchez-Tafolla BM, Chiu LM, Aldana BI and Guarneros A. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 96: 257-266. 2011.
Sitges M . Chapter 7: Antiepileptic drugs targeting cerebral presynaptic ion channels reduced cerebral excitability decreasing glutamate release. Foyaca Sibat H. (Ed.), In: “Novel Treatment of Epilepsy”. INTECH, Janeza Trdine Rijeka, Croatia. First published August, 2011. (Free online editions www.intechopen.com)
Herrera-Mundo N and Sitges M . Mechanisms underlying striatal vulnerability to 3-nitropropionic acid. J. Neurochem. 114 (2): 597-605. 2010.
Sitges M , Aldana BI, Chiu LM and Nekrassov V. Characterization of phenytoin, carbamazepine, vinpocetine and clorgyline simultaneous effects on sodium channels and catecholamine metabolism in rat striatal nerve endings. Neurochem. Res. 34: 470-479. 2009.
Nekrassov V and Sitges M . Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine. Clin. Neurophysiol. 119: 2608-2614. 2008.
Sitges M , Guarneros A. and Nekrassov V. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]Glu: Comparison with the Na+ channel-mediated release. Neuropharmacol. 53:854-862. 2007.
Sitges M Chiu LM, Guarneros A and Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]Glu in hippocampal nerve endings. Neuropharmacol. 52:598-605. 2007.
Sitges M , and Nekrassov V. Acute and chronic effects of carbamazepine, phenytoin, valproate and vinpocetine on the guinea pig BAEP parameters and threshold. Clin. Neurophysiol. 118:420-426. 2007.
Nekrassov V and Sitges M . Additive effects of antiepileptic drugs and pentylenetetrazole on hearing Neurosci. Lett. 406:276-280. 2006.
Sitges M , Chui LM and Nekrassov V. Single and combined effects of carbamazepine and vinpocetine on depolarization-induced changes in Na+, Ca2+, and glutamate release in hippocampal isolated nerve endings Neurochem. Int. 49:55-61. 2006.
Sitges M and Galindo C. Omega-agatoxin-TK is a useful tool to study P-type Ca2+ channel-mediated changes in internal Ca2+ and glutamate release in depolarised brain nerve terminals. Neurochem. Int. 46: 53-60. 2005.
Sitges M , Galván E and Nekrassov V. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes Neurochem. Int. 46: 533-540. 2005.
Galindo C and Sitges M . Dihydropiridines mechanism of action in striatal nerve endings. Comparison with ω-Agatoxin IVA. Neurochem. Res. 29: 659-669. 2004.
Galván E and Sitges M . Characterization of the participation of sodium channels on the rise in Na+ induced by 4-aminopyridine (4-AP) in synaptosomes. Neurochem. Res. 29: 347-355. 2004.
Nekrassov V and Sitges M . Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res. 60: 63-71. 2004.
Sitges M and Nekrassov V. Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin. Neurophysiol. 115: 2711-2717. 2004.
Nekrassov V and Sitges M . Changes in brainstem auditory evoked potentials (BAEPs) and hearing loss induced by pentylenetetrazole and 4-aminopyridine at convulsing doses in the guinea pig in vivo. Epilepsy Res. 53: 245-254. 2003.